ADP-Ribosylation Factor 6 Regulates Tumorigenic and Invasive Properties In vivo

Vandhana Muralidharan-Chari,† Holly Hoover,† James Clancy,† Jill Schweitzer,† Mark A. Suckow,‡,¶ Crislyn D’Souza-Schorey,∥ and Valerie Schroeder,‡ Francis J. Castellino,‡ Jeffrey S. Schorey,∥ and Crislyn D’Souza-Schorey†

Department of Biological Sciences,† Freimann Life Science Center, and W.M. Keck Center for Transgene Research, University of Notre Dame, Notre Dame, Indiana

Abstract
This study shows that the small GTP-binding protein ADP-ribosylation factor 6 (ARF6) is an important regulator of tumorigenesis and metastasis. Using spontaneous melanoma cell lines, tumor growth assays and experimental metastasis assays in nude mice, we show that sustained activation of ARF6 reduces tumor mass growth but significantly enhances the invasive capacity of tumor cells. In contrast, mice injected with tumor cells expressing a dominantly inhibitory ARF6 mutant exhibited an increased tumor burden and decreased invasion and lung metastasis compared with control animals. Effects on tumor growth correlated with reduced cell proliferation capacity and are linked at least in part to alterations in mitotic progression induced by defective ARF6 cycling. Furthermore, phospho-ERK levels in subcultured cells from ARF6(GTP) and ARF6(GDP) tumor explants correlate with invasive capacity. ARF6-induced extracellular signal-regulated kinase (ERK) signaling leads to Rac1 activation to promote invadopodia formation and cell invasion. These findings document an intricate role for ARF6 and the regulation of ERK activation in orchestrating mechanisms underlying melanoma growth, invasion, and metastasis. [Cancer Res 2009;69(6):2201–9]

Introduction
Metastasis is a complex and multistep process that depends on the ability of tumor cells to successfully break away from the primary tumor and colonize at distant sites. When tumor cells detach from the primary tumor, they “invasively” invade surrounding tissues and the host circulation, followed by extravasation into distant organs (1). Increased signaling, cytoskeletal rearrangements, and the directed targeting of matrix proteases to the extracellular space, all accompany the process of tumor cell invasion (2, 3). ADP-ribosylation factor 6 (ARF6) is a member of the ARF family of the Ras superfamily of small GTPases that alternate in cells between their GTP-bound and inactive GDP-bound forms. Over the past few years, ARF6, via its well-established roles in the regulation of endosomal membrane trafficking and actin cytoskeleton remodeling, has been shown to regulate acquisition of migratory potential in a variety of cell types (4, 5). Indeed, by directing specific cargo to discrete sites at the cell surface and/or promoting the formation of surface protrusions, ARF6 has been shown to regulate phagocytosis, intercellular adhesion, and, pertinent to this study, tumor cell invasion (reviewed in ref. 5). Recent studies using in vitro cell invasion assays have indicated that in invasive melanoma, glioma, and breast cancer cell lines, the ARF6 GTPase cycle can regulate invasive potential (6–8). These studies have shown that depletion of cellular levels of ARF6 by siRNA or expression of dominant-negative ARF6 mutants, blocks tumor cell invasion, and degradation of surrounding extracellular matrix proteins (6, 7). It has also been documented that endogenous levels of active ARF6-GTP increases in response to physiologic agonists that stimulate cell invasion (6). Furthermore, screening of various breast tumor cell lines has revealed a direct correlation between ARF6 protein expression and tumor invasive capacity (7). Finally, in melanoma and glioma cell lines, ARF6-GTP has been shown to promote cell invasion at least in part by activating the extracellular signal-regulated kinase (ERK; refs. 6, 8).

The goal of this study was to examine the role of ARF6 in tumor cell invasion in vivo. Using the invasive melanoma cell line, LOX, and athymic nude mice as a model system, we have investigated the role of ARF6 in invasion and metastases by examining the effects of ARF6 mutants defective in GTP/GDP cycling. We find that the constitutive activation of ARF6 reduces tumor mass growth but significantly enhances the invasive capacity of tumor cells. Dominant inhibition of ARF6 function delays the rate of tumor growth as well as local invasion and metastases. The effects on tumor growth are linked at least in part to alterations in mitotic progression induced by defective ARF6 cycling. ARF6-regulated cell invasion is dependent on ERK activation.

Materials and Methods

Plasmids. Generation of plasmids, pTRE2-ARF6(Q67L)-HA, and pTRE2-ARF6(T27N)-HA is described in Supplementary Information. Plasmids encoding green fluorescent protein–phosphatidic acid (GFP-PABD) binding domain (9) was kindly provided by Dr. Nicholas Vitale (Centre National de la Recherche Scientifique & Universite Louis Pasteur, Strasbourg, France). Plasmids encoding Rac1(T17N) and HA-ARF6(Q67L) have been described (10).

Cell culture and transfection. LOX cell lines were cultured as previously described (6). The method for generation of stable cell lines expressing ARF6-GTP/GDP mutants is described in the Supplementary Information.

Immunofluorescent staining and microscopy. LOX cells were cultured on glass coverslips, fixed, and processed as described (6, 11). Fluorescence was visualized using a Bio-Rad or Leica laser confocal scanning system.

Cell proliferation assays. Cell proliferation was monitored by crystal violet staining as previously described (12). Additional cell proliferation...
assays and doubling time measurements are described in Supplementary Information.

**In vivo tumorigenicity and metastasis assays.** Five-week-old athymic, male mice (NIH) were maintained under environmental conditions as described in the NIH Guide for the Care and Use of Laboratory Animals (see Supplementary Information). For s.c. tumor growth experiments, mice were injected s.c. in the lumbar-dorsal region with 1 × 106 LOX cells in 0.1 mL injection medium. Mice were maintained on an irradiated, nutritionally adequate (doxycyline-free) diet. Tumor volumes were calculated according to the formula \( V = \frac{4}{3}\pi a^2b \) for estimating the volume of an ellipsoid. Mice were sacrificed up to 6 wk later or when animals displayed clinical signs suggestive of significant tumor burden. For experimental lung metastasis assays, animals were injected i.v. with 1 × 106 LOX cells in 0.2 mL injection medium via the lateral tail veins. Experiments were performed as two or three independent rounds of injections.

**Histology methods.** Mice were anesthetized, perfused with fixative, and processed for histology as previously described (13). Standard H&E and Masson’s Trichrome staining procedures were used to observe histopathologic characteristics. Tissue sections expressing GFP were labeled with To-Pro-3, a nuclear stain. For quantitation of metastases, the percentage of tumor tissue to total lung tissue was calculated using Image J software.

**In vitro cell invasion assay.** The cell invasion assay was performed as previously described (6, 11). Briefly, cells were seeded on fluorescent gelatin-coated coverslips. For quantitation of cell invasion, at least 120 cells were visualized for each experimental condition and those exhibiting gelatin degradation underneath were scored. The percentage of cells degrading gelatin was calculated as an indicator of cell invasion.

**Tumor explant subculture.** Tumors from lungs and other tissues were harvested and isolated as described (14). Cell suspensions were plated in medium containing G418 for selection of LOXGFP cells.

**ARF6-GTP pull-down assay.** Levels of ARF6-GTP were measured using a pull-down assay as previously described (15).

**Western blot analysis and antibodies.** Standard protocols were used. Antibodies used are anti-GFP (Roche), mouse anti-HA (Covance), mouse anti-Myc antibody, Clone 9B11 (Cell Signaling Technologies), anti-mouse monoclonal phospho-p44/42 ERK, E10 (Cell Signaling Technologies), anti-rabbit polyclonal p44/42 antibody (Cell Signaling Technologies), and anti-α-tubulin (Sigma).

**Cell cycle analyses and mitotic synchronization.** To analyze progression through cytokinesis, mitotic LOX cells were synchronized as previously described (15) and analyzed using immunofluorescence microscopy post entry into mitosis. Flow cytometry was performed using a Cytomics FC-500 flow cytometer (Beckman Coulter) and the percentage of cells undergoing apoptosis in each phase of the cell cycle phase was determined according to an internal protocol.

**Results**

**Characterization of LOX cells expressing ARF6 GTP/GDP cycling-defective mutants.** LOX is a highly invasive melanoma cell line. For these investigations, we generated clonal populations of LOX cell lines capable of stable expression of hemagglutinin (HA)-tagged constitutively activated GTP-bound, and dominant-negative GDP-bound ARF6 mutants, ARF6(Q67L)-HA, and ARF6(T27N)-HA, respectively, as well as GFP. Western analysis was performed on all Tet-Off clones surviving selection to confirm transgene expression (Supplementary Fig. S1A). In addition, lysates were subjected to an ARF6-GTP pull-down assay (15). As expected, lysates from the ARF6(Q67L) stable LOX cells exhibited a high level of ARF6-GTP compared with the parental and ARF6(T27N)-LOX cells (Supplementary Fig. S1B). Endogenous ARF6 levels were similar in parental, stable GFP, and mutant ARF6-LOX cell lines. Immunofluorescent staining showed that consistent with previous observations (6), ARF6(GDP) is predominantly localized to the perinuclear cytoplasm, whereas ARF6(GTP) is predominantly localized to the cell surface of LOXARF6-GFP and LOXARF6-GTP cells, respectively (Supplementary Fig. S1C). Cell lines expressing GFP, ARF6(Q67L), and ARF6(T27N) will henceforth be called LOXGFP, LOXARF6-GFP, and LOXARF6-GTP, respectively.

The ARF6 GTP/GDP cycle regulates tumor growth. LOXGFP, LOXARF6-GFP, and LOXARF6-GDP cells were injected s.c. into the flanks of 5-week-old athymic, male mice. All cells lines injected formed palpable tumors by 1 week. Primary tumors formed from LOXGFP cells had a steady growth rate over time. These mice formed large s.c. tumors and were sacrificed at early time points to minimize tumor burden in accordance with animal care guidelines. Tumors formed by LOXARF6-GDP cells also grew slowly, albeit not to the same degree and at a slower rate relative to LOXGFP control tumors (Fig. 1A and B). In marked contrast, however, primary tumors formed by LOXARF6-GTP cells remained notably small.

To confirm that alterations in tumor volume were direct effects of expressing ARF6 mutants, we analyzed the growth rate of the LOXGFP, LOXARF6-GTP, and LOXARF6-GDP cells using in vitro proliferation assays. LOX cells were plated and counted (Supplementary Fig. S2A), or stained with crystal violet over a period of 4 days (Fig. 1C). As shown, LOXARF6-GDP cells grew slightly slower with doubling time of 24.8 ± 0.9 hours, compared with 22.4 ± 2.1 hours in parental LOXGFP cells. However, the LOXARF6-GTP cell line grew at a significantly reduced rate with a doubling time of 34.2 ± 1.4 hours. We also assessed the relative levels of Myc in each of the stable cell lines. Myc coordinates gene expression involved in cell cycle progression and contributes to tumorigenesis by inducing unrestrained cellular growth and proliferation (16). We found that the levels of Myc were similar in LOXGFP and LOXARF6-GFP cells but dramatically decreased in LOXARF6-GTP cells, as measured by Western analysis (Fig. 1D). We performed cell cycle analysis on the LOX lines (Fig. 2A) and cells obtained from the primary tumor (Supplementary Table S1). Although there is no block during progression through the cell cycle, there is a small increase in the number of cells in the G2-M phase with expression of the ARF6-GDP mutant. However, we find a more pronounced increase in LOXARF6-GTP cells in G2-M along with a significant decrease in the number of cells in the S phase. Also, there are no major alterations in the cells undergoing apoptosis. To further confirm that the reduced growth rate of the LOXARF6-GTP stable line was due to a decrease in proliferation and not cell death, lactate dehydrogenase (LDH) release was measured (data not shown).

After 4 days of culture, LDH levels remained similarly low in all cell lines tested, suggesting that the decreased proliferation rate in LOXARF6-GTP cells is not due to an increase in cell death (data not shown).

Constitutive activation of ARF6 in cell culture results in a significant delay in the completion of cytokinesis, the terminal stage of mitosis (11, 17). To determine whether the decrease in tumor growth in LOXARF6-GTP cells correlates with changes in cytokinesis, cells subcultured from LOXARF6-GTP tumors were examined for progression through mitosis. Cells were synchronized using double-thymidine block followed by nocodazole arrest. Although all the synchronized cells reached late telophase/early cytokinesis by 90 minutes after entry into mitosis, LOXARF6-GTP cells frequently remained connected by thin tubulin-positive intercellular bridges at 4 to 5 hours after mitotic entry (Fig. 2B).

http://rsb.info.nih.gov/ij/
Although only 3.7% of parental LOX cells exhibited this phenotype, ~3- to 6-fold more LOX<sup>ARF6-GTP</sup> cells, either the parental cell line or those derived from the primary tumor, were still connected. Thus, the decrease in cell proliferation leading to reduced tumor growth is due at least in part to aberrant effects of ARF6-GTP on the cell division machinery.

**Effect of ARF6 on primary tumor invasion.** In addition to tumor growth, we also monitored the invasive capabilities

---

**Figure 1.** Growth characteristics of primary LOX tumors and LOX cell lines. A and B, mice were injected s.c. with LOX<sup>GFP</sup>, LOX<sup>ARF6-GDP</sup>, or LOX<sup>ARF6-GTP</sup> cells in the dorsal flank. Photographs of representative tumors at 3 wk postinjection are shown.Progression of tumor volumes at the indicated days postinjection is plotted. C, 2.5 × 10<sup>5</sup> LOX<sup>GFP</sup>, LOX<sup>ARF6-GDP</sup>, and LOX<sup>ARF6-GTP</sup> cells were plated in triplicate, stained with crystal violet, and the proliferation rates are shown as an average of two independent experiments. D, lysates from respective cell lines were subjected to SDS-PAGE and probed with Myc, HA, GFP, and α-tubulin (loading control) antibodies. A representative blot is shown. The graph displays the densitometric intensity of the Myc band from three independent experiments. Columns, mean; bars, SD; **, P < 0.002.
of the primary tumors formed by LOX<sup>GFP</sup>, LOX<sup>ARF6-GTP</sup>, and LOX<sup>ARF6-GDP</sup> cells. S.c. injections of melanoma as described above allows cell invasion through the subcutaneous muscle, fat, and dermal layers (reverse metastases); therefore, examination of the tumor-skin interface serves as a good indicator of localized invasion. Thus, serial sections from tumors at the tumor-skin interface were analyzed for GFP or stained with Masson's Trichrome. Supplementary Fig. S3A and B show the progression of the primary tumors formed by LOX<sup>GFP</sup>, LOX<sup>ARF6-GTP</sup>, and LOX<sup>ARF6-GDP</sup> cells. S.c. injection of melanoma as described above allows cell invasion through the subcutaneous muscle, fat, and dermal layers (reverse metastases); therefore, examination of the tumor-skin interface serves as a good indicator of localized invasion. Thus, serial sections from tumors at the tumor-skin interface were analyzed for GFP or stained with Masson's Trichrome. Supplementary Fig. S3A and B show the progression
of LOX\textsuperscript{GFP} invasion with time. At 3 weeks postinjection, these cells showed a high degree of cell invasion, as measured by the extent of collagen border compromise and infiltration into surrounding muscle and skin. Expression of ARF6 GTP/GDP mutants significantly affected the kinetics of LOX invasion. Approximate time-matched LOX\textsuperscript{ARF6-GDP} tumors displayed cell invasion, although to a much reduced extent relative to LOX\textsuperscript{GFP} because in some areas, the tumor border at the tumor-skin interface remained largely intact and did not display evidence of invasion (Fig. 3). Time-matched LOX\textsuperscript{ARF6-GTP} tumors on the other hand, although four to five times smaller than the LOX\textsuperscript{GFP} tumors, were significantly more invasive (Fig. 3). Large areas of the collagen border and muscle tissue surrounding the primary tumor mass were completely obliterated and replaced by ARF6-GTP–expressing tumor cells. When size-matched LOX\textsuperscript{GFP} and LOX\textsuperscript{ARF6-GTP} tumors were compared, the effect of sustained ARF6 activation on invasion potential is even more pronounced (Fig. 4A–C). Although the border of relatively small LOX\textsuperscript{GFP} tumors measuring ~400 mm\textsuperscript{2} is intact, ARF6-GTP–expressing tumors in the same size range showed compromise to the tumor border at the tumor-skin interface and localized invasion into surrounding fat tissue. In a second set of size-matched experiments, LOX\textsuperscript{ARF6-GTP} primary tumors were allowed to grow for ~57 days to enlarge their masses to a size comparable with that of invasive LOX\textsuperscript{GFP} tumors (~4,000 mm\textsuperscript{3}). These larger primary ARF6-GTP tumors invaded far into the epidermis and the collagen border, muscle cells, and subcutaneous fat layers were markedly compromised (Fig. 4D–F). This was significantly more invasive than that observed for size-matched LOX\textsuperscript{GFP} tumors. Figure 4G to H compares sections of LOX\textsuperscript{GFP} and LOX\textsuperscript{ARF6-GTP} tumors demonstrating a similar degree of invasion into surrounding tissues. The collagen and muscle layers exhibit a comparable extent of compromise. Of note is that the LOX\textsuperscript{ARF6-GTP} tumor shown is 25% the size of the LOX\textsuperscript{GFP} tumor. Collectively, these findings indicate that although sustained ARF6 activation reduces tumor mass growth, it confers significant invasive potential to cells of the primary tumor.

**Effect of ARF6 on experimental lung metastasis.** Studies with metastasis models of athymic nude mice have shown that LOX cells have a preference for growth in the lungs (18, 19). However, reverse metastases often decreases the efficiency at which these melanoma cells reach the lung. Therefore, in addition to the spontaneous metastasis model, an experimental metastasis assay that has been used extensively to study the events that occur after intravasation (14, 18) was used to observe the effects of ARF6 on metastatic behavior in vivo. For these latter studies, 1 × 10\textsuperscript{6} cells were injected into the tail vein and mice were observed on a regular basis for respiratory dyspnea, and time-matched sets of mice were sacrificed when signs of distress were apparent. Gross pathologic examination of lungs showed that mice injected with LOX\textsuperscript{GFP} cells had the greatest extent of metastatic burden. These mice sacrificed at 43 or 53 days postinjection displayed numerous micrometastatic lesions (Fig. 5A). Mice injected with LOX\textsuperscript{ARF6-GDP} cells displayed a moderate degree of metastatic burden at the same postinjection times, and lungs from these mice had fewer and smaller micrometastatic lesions compared with lungs from LOX\textsuperscript{GFP}-injected mice (Fig. 5A). Furthermore, the incidence of lung metastases was 43% relative to 67% in LOX\textsuperscript{GFP}-injected mice. We also observed metastatic lesions in the lymph nodes, soft tissues associated with stifle joint and testicular tissues. In stark contrast, lungs from mice injected with LOX\textsuperscript{ARF6-GTP} cells did not show any visible macroscopic metastases even at longer postinjection times (Fig. 5A).

Lungs were also examined for micrometastases. In accord with gross examination, lungs from mice injected with LOX\textsuperscript{GFP} cells showed the greatest degree of tumor burden where much of the lung tissue was replaced by tumor cells (Fig. 5B). Lungs excised
from mice injected with LOX\textsuperscript{ARF6-GDP} cells showed several small tumors in most of the lobes (Fig. 5\textit{B}). However, the lungs obtained from mice injected with LOX\textsuperscript{ARF6-GTP} cells exhibited only microscopic metastases that were not detectable by gross examination (Fig. 5\textit{B}, far right column). Thus, sustained activation of ARF6, such as its effect on primary tumor growth, dramatically reduces the efficiency of macrometastases formation.

In our previous investigations, we showed that expression of dominant-negative ARF6-GDP in LOX cells abolished invadopodia formation and, hence, cell invasion in \textit{in vitro} assays for cell invasion (6). Given the findings described here, we examined the ability of metastasized LOX\textsuperscript{ARF6-GDP} cells to form invadopodia. To this end, we generated several subcultures from LOX\textsuperscript{GFP} and LOX\textsuperscript{ARF6-GDP} macrometastases in lung, lymph nodes, and testis, resulting from lateral tail vein injections. Representative fluorescence and phase contrast images of the LOX\textsuperscript{GFP} and LOX\textsuperscript{ARF6-GDP} subcultured cells are shown in Supplementary Fig. S4. We were unable to generate subcultures from the LOX\textsuperscript{ARF6-GTP} lung metastases, likely due to their reduced capacity to proliferate in addition to limited cell numbers. As seen in Fig. 5\textit{C}, when seeded on gelatin-coated coverslips and labeled for cortactin, a bone fide component of invadopodia, unlike the parental LOX\textsuperscript{ARF6-GDP} cell line, LOX\textsuperscript{ARF6-GDP} cells subcultured from tumor explants exhibit prominent invadopodia, suggesting that compensatory pathways in tumors come into play to rescue invasiveness.

**ERK activation in metastatic tumor explants.** Previous studies also showed that ARF6-regulated invasion was dependent on ERK activity (6, 8). ARF6-GTP facilitated ERK activation, whereas ARF6-GDP–expressing cells exhibited significantly lower levels of activated ERK relative to invasive LOX cells. Thus, we examined the levels of phospho-ERK levels in LOX\textsuperscript{ARF6-GDP} cells subcultured from tumor explants compared with their parental counterparts. However, phospho-ERK levels in the LOX\textsuperscript{ARF6-GDP} subcultured cell lines are higher than the parental line (Fig. 5\textit{D}). These findings suggest that the LOX\textsuperscript{ARF6-GDP} cells that were capable of colonizing at secondary sites had overcome the inhibitory effects of mutant ARF6 on ERK activation. Given this finding, ERK activity was also examined in LOX\textsuperscript{ARF6-GDP} primary tumors. We found that the level of phospho-ERK was dependent on tumor size, as LOX\textsuperscript{ARF6-GDP} cells cultured from larger tumors exhibited higher phospho-ERK levels compared with cells derived from the smallest tumor or the parental cell line (Fig. 5\textit{D}). Thus, compensatory mechanisms are in place to rescue ERK signaling in LOX\textsuperscript{ARF6-GDP} cells \textit{in vivo}. ERK levels stayed relatively constant in cell lines subcultured from the LOX\textsuperscript{ARF6-GTP} and LOX\textsuperscript{GFP} primary tumors (data not shown).

Phospholipase D (PLD) activity is elevated in a large variety of cancers (20, 21). PLD also promotes ERK activation by increasing the membrane-associated pool of phosphorylated Raf (22, 23). ARF6 activates PLD and a role for PLD has been described in ARF6-regulated endosome recycling, epithelial cell migration, and regulated secretion (5). We hypothesized that ARF6 promotes ERK phosphorylation during cell invasion by activating PLD activity. Indeed, we find that phospho-ERK levels in LOX\textsuperscript{GFP} and

![Figure 5. Experimental metastasis of LOX\textsuperscript{ARF6-GTP} and LOX\textsuperscript{ARF6-GDP} cells. A, photographs of whole lungs from representative LOX\textsuperscript{GFP}, LOX\textsuperscript{ARF6-GDP}, or LOX\textsuperscript{ARF6-GTP} mice post tail vein injection at 43, 53, and at 61 d, respectively. The lungs of mice injected with LOX\textsuperscript{GFP} showed the greatest extent of macrometastatic lesions in each lobe. LOX\textsuperscript{ARF6-GTP}–injected mice exhibited fewer and smaller macrometastatic lesions. No visible metastatic lesions were seen in LOX\textsuperscript{ARF6-GDP}–injected mice. The percentage of tumor tissue to total lung tissue is indicated. H, heart; T, tumor. B, histologic analysis of lungs from experimental metastasis assays. Top and bottom, representative sections from LOX\textsuperscript{GFP}, LOX\textsuperscript{ARF6-GTP}, and LOX\textsuperscript{ARF6-GDP} lung tumors at \textit{x} \times 10, \textit{x} \times 5, and \textit{x} \times 20 magnification, respectively. All lungs were time matched at 53 d post tail-vein injection. C, characterization of invasiveness in LOX\textsuperscript{ARF6-GDP} and subcultured LOX\textsuperscript{ARF6-GDP} cells. Parental LOX\textsuperscript{ARF6-GDP} and subcultured LOX\textsuperscript{ARF6-GDP} cells from lung tumors were plated on FITC-gelatin–coated coverslips (green) and allowed to invade (top and bottom, respectively). Cells were fixed and stained for actin (red) and cortactin (blue) and imaged using confocal microscopy. Arrowhead, protruding invadopodia. D, ERK activation in invasive LOX\textsuperscript{ARF6-GDP} lysates were prepared from parental LOX\textsuperscript{ARF6-GDP} cells and from cells subcultured from metastatic tumors (left) or from primary tumors ranging from 300 to 5,000 mm\textsuperscript{3} in size (right) and subjected to Western Blot analysis. Blots were probed for phospho-ERK, total ERK, and \textit{α}-tubulin (loading control). Band density was measured by densitometry, and the ratios of ERK to phospho-ERK is shown. A representative blot of three separate experiments is shown.](image-url)
LOXARF6-GTP cells subcultured from the primary tumor are decreased upon treatment with primary alcohols such as 1-butanol that interrupts PLD catalyzed formation of phosphatidic acid (PA). Treatment with 4-butanol was used as a control (Fig. 6A). Next, we investigated PLD activity in LOXARF6-GDP subcultures from sites of metastases relative to the original LOXARF6-GDP cell line by examining the accumulation of PA using a fluorescent probe, GFP-PA binding domain (GFP-PA binding domain of SNAP 25), shown to function as a specific sensor of PA (9). As seen in Fig. 6B, PLD activity was significantly higher in LOXARF6-GDP cells subcultured cells, suggesting that in the absence of ARF6 activation, other signals ensue in vivo to elevate PLD activity. Inhibition of PLD activity, as described above, blocked ERK phosphorylation in these subcultured cells (Supplementary Fig. S5A). PLD inhibition also blocked invadopodia formation and cell invasion in LOXARF6-GDP cells subcultured cells in vitro assays (Supplementary Fig. S5B and C).

Figure 6. PLD activity is required for ERK activation, and Rac1 activation downstream of ERK is required for cell invasion. A, LOXGFP, LOXARF6-GDP, and LOXARF6-GTP cells were treated with 0.3% of 4-butanol or 1-butanol as indicated. Cell lysates were probed for phospho-ERK or total ERK by Western blotting. The blots were reprobed with β-tubulin as a loading control. Band density was measured by densitometry, and the ratios of ERK to phospho-ERK is shown. B, Images of LOXARF6-GDP and subcultured LOXARF6-GDP cells from metastatic tumor explants expressing GFP-PA binding domain (green), and stained with HA antibody to detect ARF6-GDP, are shown. Identical acquisition settings were used to image GFP-PA binding domain in each sample. C, Rac1 activation occurs downstream of ERK signaling during cell invasion. LOXGFP, LOXARF6-GDP, and LOXARF6-GTP cell lines and LOXARF6-GDP cells from metastasized tumors seeded on serum-coated coverslips and allowed to invade in the presence or absence of 20 μmol/L U0126. Lysates of cells for each condition were then subjected to the PAK-binding assay and immunoblotted for Rac1. Cell lysates were also probed for total Rac1 and for β-tubulin (loading control). Band density was measured by densitometry, and the ratio of Rac1-GTP to total Rac1 is shown. D, inactivation of Rac1 inhibits basal and ARF6-GTP-induced invasion. LOX cells were transiently transfected with plasmid expressing Rac1(T17N) alone or with an expression plasmid for HA-ARF6(Q67L) and seeded on FITC-gelatin–coated coverslips. Cells were fixed and labeled for Rac1 or for Rac1 and HA. Cells expressing with Rac1(T17N) alone or coexpressing Rac1(T17N) and ARF6(Q67L) and exhibiting matrix degradation underneath were scored and the percentage of invasion is shown.
How does ERK activation downstream of ARF6 promote cell invasion? We examined Rac1 activation in LOX, LOXARF6-GTP cell lines, and invasive subcultured LOXARF6-GDP cells because (a) Rac1 activation downstream of ERK has been shown to have a role in cell invasion (24) and (b) Rac1 activation downstream of ARF6 has been shown to regulate cell motility (5). We show that Rac1-GTP levels are increased in LOXARF6-GTP cells and subcultured LOXARF6-GDP cells relative to basal Rac1-GTP in LOX cell lines (Fig. 6C). In all three cell lines, Rac1 activation was abolished by treatment with MAP/ERK kinase inhibitors, suggesting that Rac1 activation occurs downstream of ERK (data not shown). In in vitro cell invasion assays, expression of dominant-negative Rac1 blocked basal as well as ARF6-GTP induced cell invasion (Fig. 6D). Taken together these studies suggest that ARF6→PLD→ERK→Rac1 module regulates the process of tumor cell invasion.

Discussion

Here, we report on the results of an in vivo study in which the effects of perturbing the ARF6 GTP/GDP cycle on the tumorigenic and metastatic progression of melanoma was examined. We used a well-characterized mouse model to investigate the effect of ARF6 mutants on subcutaneous melanoma tumor growth and lung metastasis. Sustained activation of ARF6 through the expression of an ARF6-GTP mutant hampered growth of the primary tumor but augmented the invasive potential of LOX cells in the primary tumor. The expression of dominant-negative ARF6, ARF6(T27N), slowed down the growth rate of the primary tumor mass and by and large showed a reduction in the degree of primary tumor cell invasion into the surrounding tissue. Furthermore, lungs excised from mice injected i.v. with LOXARF6-GDP cells displayed a lower incidence of lung metastasis and less tumor burden compared with lungs of control animals. This work is consistent with our previous work wherein the effects of GTP/GDP cycling ARF6 mutants were examined in LOX cells using in vitro cell invasion assay.

The constitutive activation of ARF6 enhances invasive capacity via ERK activation (6). We show that ERK signaling in ARF6 tumors is dependent on PLD activation. The current study also suggests that compensatory mechanisms are in place that rescue deficient PLD and ERK signaling in the LOXARF6-GDP cells in vivo, as cells cultured from LOXARF6-GDP primary or lung tumor explants exhibited higher phospho-ERK levels compared with the parental cells. How might ARF6-PLD-ERK signaling promote cell invasion? Our previous studies have shown that ARF6 activation increases the rate of invadopodia turnover, making cells more invasive (6). Indeed, inhibition of PLD and ERK blocks invadopodia formation in cells isolated from LOX and LOXARF6-GTP tumors. Furthermore, cells derived from LOXARF6-GDP tumor explants regain the ability to form invadopodia. The studies shown here also indicate that ERK activation leads to increased Rac1-GTP levels and invadopodia formation is dependent on Rac1 activation downstream of ERK activation. Rac1 activation in turn could promote actin remodeling required for invadopodia extension or facilitate the recruitment of actin-binding proteins as has been described (17). In addition to its control of invadopodia formation, ARF6 might also regulate the trafficking/release of proteases such as the membrane type metalloproteases (25) at the invasive front.

The slow growth rate of LOXARF6-GTP tumors correlated with a reduced proliferation rate in vitro. A low level of Myc expression, a marker for cell proliferation, in LOXARF6-GTP cells relative to parental LOX cells, also correlates with reduced cell proliferation. These findings are in alignment with previous reports by us and others that the efficiency of completion of cytokinesis is significantly reduced upon sustained activation of ARF6 (26–28). As described here, sustained ARF6 activation leads to an increase in primary tumor cells at the G2-M stage of the cell cycle. At this time, we cannot exclude a direct role for ARF6 in other cell proliferation signaling responses that may also account for the dramatic decrease in proliferation rate observed in LOXARF6-GTP tumors. The dramatic effect of active ARF6 on cell proliferation was evident also in the development of metastatic foci in the lungs. Typically individual tumor cells proliferate to form microscopic nodules that eventually form macrometastatic lesions. LOXARF6-GTP cells did not lead to any visible macroscopic lesions in the lung as opposed to LOXGFP cells where macroscopic lesions were clearly evident. Lesions were also observed in animals injected with LOXARF6-GDP cells, although these were smaller and of lower incidence relative to control animals. These studies suggest that ARF6 cycling may be required for the development of macrometastases at distal sites.

Whether there is a direct correlation between tumor size and disease prognosis is still ambiguous, although studies have indicated that the probability of developing metastases increases with tumor size (29). Of important note however is that the ARF6-GTP tumors despite their small size are significantly more invasive than their parental counterparts. Similar opposing effects on tumor size and invasion capacity have been reported in skin carcinogenesis models of p53 and Tiam 1–deficient mice (30, 31). These apparently opposing effects of ARF6 activation on tumor cell proliferation and invasion may indeed be a reflection of a requirement for ARF6 cycling, and that its altered regulation could have varying outcomes during the different stages of tumor progression.

Given the functions of ARF6 in many cellular processes and pathways, our results support accumulating evidence that ARF6 coordinates mechanisms underlying tumor cell proliferation, motility, and invasion—all of which are crucial for tumor growth, maintenance, and metastasis. These findings have widespread implications for the function of ARF6 as a potent regulator of tumor growth and metastatic behavior in vivo.

Note Added in Proof

Since this article was accepted, Hu et al. reported that ARF6 regulates glioma cell invasion via a Rac1-dependent pathway. (Cancer Research 2009;69:794–801).

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

Received 4/9/2008; revised 12/16/2008; accepted 1/12/2009; published OnlineFirst 3/10/09.

Grant support: A subproject of a Program Project Grant to the Notre Dame-Walter Cancer Center from the Department of Defense, U.S. Army Medical Research, and Materiel Command (C.D. Souza-Schorey and J. Schorey), and by a grant from the NIH (CA115316-01; C.D. Souza-Schorey). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dr. Felipe Palacios for the pTRE2:ARF6 mutant plasmids, Dr. Julia Knight (Mathematics, Notre Dame) for invaluable assistance with doubling time measurements, Linda Van Aelst and Philippe Chavrier for helpful comments, and Kundus Kruger-Passig and Mayra Sandoval-Cooper for excellent technical assistance.

Cancer Res 2009; 69: (6). March 15, 2009 2208 www.aacrjournals.org

Downloaded from cancerres.aacrjournals.org on August 14, 2021, © 2009 American Association for Cancer Research.
References

ADP-Ribosylation Factor 6 Regulates Tumorigenic and Invasive Properties *In vivo*

Vandhana Muralidharan-Chari, Holly Hoover, James Clancy, et al.


**Updated version**
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-08-1301

**Supplementary Material**
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2009/03/05/0008-5472.CAN-08-1301.DC1

**Cited articles**
This article cites 31 articles, 17 of which you can access for free at:
http://cancerres.aacrjournals.org/content/69/6/2201.full#ref-list-1

**Citing articles**
This article has been cited by 32 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/69/6/2201.full#related-urls

**E-mail alerts**
Sign up to receive free email-alerts related to this article or journal.

**Reprints and Subscriptions**
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

**Permissions**
To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/69/6/2201.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.